TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 5, 2025
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of comprehensive income (loss)
| Year ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net income (loss) | $(1,959) | $(615) | $(2,499) |
| Other comprehensive income (loss), net of tax: | |||
| Currency translation adjustment | (530) | 80 | (356) |
| Unrealized gain (loss) on derivative financial instruments, net | 28 | 29 | 29 |
| Unrealized gain (loss) on defined benefit plans, net | (6) | (18) | 57 |
| Total other comprehensive income (loss) | (508) | 91 | (270) |
| Total comprehensive income (loss) | (2,467) | (524) | (2,769) |
| Comprehensive income (loss) attributable to non-controlling interests | (381) | (106) | (169) |
| Comprehensive income (loss) attributable to Teva | $(2,086) | $(418) | $(2,600) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.